Overview Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy Status: Recruiting Trial end date: 2023-08-15 Target enrollment: Participant gender: Summary The study is an open label, non-randomized study designed to evaluate the diagnostic performance of SPECT CT. Phase: Phase 1 Details Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsCollaborator: National Cancer Institute (NCI)